tirzepatide or zepbound Zepbound® (Tirzepatide) Prescribed Online with Ongoing Care Compounded Tirzepatide vs. Zepbound –

Hdersdal S, Andersen A, Knop FK, Vilsbll T (2023) Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases

Our Research Lead examined anonymized platform data from: 5,864 US adults using tirzepatide (Mounjaro or Zepbound) 4,456 US adults using semaglutide (Ozempic or Wegovy) Inclusion criteria: Active GLP-1 therapy with weekly injections Minimum 12-week tracking duration Adherence threshold: 1 injection log and 1 weight entry per week No weight entries outside physiological bounds (30300 kg) or with weekly changes exceeding 5% Primary outcome: Percentage body weight change from baseline, calculated as [(current weight baseline weight) / baseline weight] 100 , where negative values indicate weight loss Data collection period: Data were collected from all available platform records through January 2026, representing naturalistic use patterns without researcher intervention

The GLP-1-activated neurons in the brain also limit appetite for a while after a large meal (e.g., the thought of eating is unappealing for many hours after pigging out on pizza).[ref] Stress-related appetite suppression: Additionally, the GLP-1 neurons activate during times of acute stress to suppress appetite

Estruch, R

Suggested Add-Ons: NAD, Zofran, Toradol, B12, Taurine, Glutathione